Welcome to our dedicated page for Acurx Pharmaceuticals SEC filings (Ticker: ACXP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acurx Pharmaceuticals, Inc.'s SEC filings document a late-stage biopharmaceutical issuer developing antibiotics for difficult-to-treat Gram-positive bacterial infections. Registration statements describe securities offerings, resale registration mechanics, common stock, warrants and the company's status as an emerging growth company and smaller reporting company.
ACXP's Form 8-K filings record material events tied to capital structure, governance and compensation, including amendments to authorized common shares and executive and director compensation arrangements. The filings also cover Nasdaq-listed common stock, operating and financial results, material agreements, shareholder voting matters and risk disclosures associated with antibiotic research and development.
Acurx Pharmaceuticals, Inc. is filing an S-1 to register the resale of up to 1,650,170 shares of common stock issuable upon exercise of Series H warrants with a $2.78 per share exercise price. Only selling stockholders will receive resale proceeds; Acurx would receive up to about $4.6 million if all warrants are exercised for cash. These Series H warrants were issued in an April 2026 private placement tied to a concurrent $2.5 million registered direct offering. Acurx is a late-stage biopharmaceutical company developing Gram-positive targeted antibiotics and its stock trades on Nasdaq under the symbol ACXP.
Acurx Pharmaceuticals director Carl Sailer received a stock option grant tied to his service on the company’s board. The award covers 2,150 options for Common Stock at an exercise price of $2.36 per share.
The options were granted as part of Acurx’s Director Compensation Policy and will fully vest on April 20, 2027. Following this award, Sailer holds stock options for 2,150 underlying shares, which are scheduled to expire on April 20, 2036.
Acurx Pharmaceuticals director Jack H. Dean received a compensatory stock option award for service on the company’s board. The grant covers 2,150 shares of common stock at an exercise price of $2.36 per share, expiring on April 20, 2036.
The option was granted at no cost and is scheduled to vest in full on April 20, 2027 under Acurx’s Director Compensation Policy. This Form 4 reports an option grant only; it does not show any open‑market purchases or sales of Acurx common stock by the director.
Acurx Pharmaceuticals director James J. Donohue received a stock option grant covering 2,150 shares of common stock as board compensation. The option has an exercise price of $2.36 per share, vests on April 20, 2027, and expires on April 20, 2036. Following the grant, he holds 2,150 stock options directly.
Acurx Pharmaceuticals, Inc. director Thomas L. Harrison received a stock option award as compensation for service on the company’s board of directors. The grant covers 2,150 stock options for common stock at an exercise price of $2.36 per share.
The options were awarded at no upfront cost and will vest on April 20, 2027, meaning they become exercisable on that date. The options are scheduled to expire on April 20, 2036 if not exercised. Following this grant, Harrison holds stock options covering 2,150 shares directly.
Acurx Pharmaceuticals, Inc. director Joseph C. Scodari received a stock option grant related to his service on the company’s board. The award covers 2,150 stock options for common stock at an exercise price of $2.36 per share, with all options vesting on April 20, 2027.
The options expire on April 20, 2036. After this grant, Scodari holds 2,150 stock options directly, reflecting a compensation-related award rather than an open‑market share purchase or sale.
Acurx Pharmaceuticals director Robert J. DeLuccia received a compensation grant of stock options covering 37,100 shares of common stock. The options were granted on April 20, 2026 with an exercise price of $2.36 per share and expire on April 20, 2036.
The options vest in 36 equal monthly installments starting on the grant date, meaning the award vests gradually over three years. Following this grant, DeLuccia holds stock options for 37,100 underlying shares directly, with no additional derivative positions shown in this filing.
Acurx Pharmaceuticals, Inc. reported that President and CEO David P. Luci received a grant of stock options. On April 20, 2026, he was granted options to purchase 37,100 shares of common stock at an exercise price of $2.36 per share.
The options vest in 36 equal monthly installments starting on the grant date and expire on April 20, 2036. Following this grant, he holds 37,100 stock options directly, each tied to one underlying share of Acurx common stock.
Acurx Pharmaceuticals, Inc. reported that its Chief Financial Officer, Robert G. Shawah, received a grant of stock options covering 25,900 shares of common stock on April 20, 2026.
The options have an exercise price of $2.36 per share, expire on April 20, 2036, and vest in 36 equal monthly installments starting on the grant date. After this grant, he holds stock options for 25,900 shares directly as reported in this filing. This is a compensation-related award rather than an open-market share purchase or sale.
Acurx Pharmaceuticals is raising equity capital through a registered direct offering with a concurrent private placement of warrants. The company agreed to sell 816,068 common shares at $3.03 per share and pre-funded warrants for up to 9,017 shares at $3.029, for aggregate gross proceeds of about $2.5 million before fees.
In the private placement, investors will receive Series H warrants to purchase up to 1,650,170 shares of common stock at an exercise price of $2.78 per share, exercisable immediately and expiring 24 months after the resale registration becomes effective. If these warrants are fully exercised for cash, the company could receive up to an additional $4.6 million.
The company plans to use net proceeds for working capital and general corporate purposes, has agreed to a 15-day lock-up on most new equity issuances after closing, and will avoid variable rate transactions for one year except for a potential at-the-market program and an equity line of credit.